Biotech Startups

Anaconda Biomed develops next-generation endovascular access and protection devices. The company serves the medical device market, focusing on vascular intervention procedures.

3 investors

Andson Biotech develops analytical tools for the analysis of biotherapeutics, aimed at supporting the discovery and development of biologic drugs.

3 investors

AnimalBiome develops microbiome testing and probiotic products for dogs and cats to improve digestive health and overall wellness. The company serves pet owners and veterinarians through science-based solutions focused on understanding and optimizing the pet gut microbiome.

3 investors

Animate Biosciences develops peptide therapeutics that target pathological tissue remodeling, using an AI platform trained on multi-omic data from highly regenerative organisms to design novel peptides. The company applies regenerative biology and machine learning to rebuild tissue and organ systems for conditions with limited treatment options.

3 investors

ANNAIDA develops non-invasive technology to analyze cellular chemistry and metabolic properties without damaging microscopic life. The company serves researchers and scientists studying cells, embryos, stem-cell organoids, and other cellular materials.

3 investors

Annexon is a clinical-stage biopharmaceutical company developing C1q and classical complement pathway inhibitors to treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. Its pipeline targets diseases of the body, brain, and eye, including Guillain-Barré syndrome and geographic atrophy.

3 investors

Anodyne Nanotech develops the HeroPatch, a transdermal drug delivery system designed to replace traditional injections for chronic care treatments. The company focuses on simplifying medicine delivery through an alternative to needles and syringes.

3 investors

Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients. The company's lead candidate, AT-7687, is a clinical-stage peptide designed to block dysfunctional biological pathways contributing to fat storage and metabolic dysfunction, offering an alternative treatment approach with improved tolerability.

3 investors

Anto is an AI research lab developing foundation models for microbial communities to enable precision medicine by computationally modeling how the microbiome affects individual drug response. The company serves pharmaceutical and clinical research by combining AI with genomic and microbiome data.

3 investors

Aperiam Bio uses computer-vision algorithms to identify "hyperfolding" protein variants with improved expression, solubility, and stability, aiming for order-of-magnitude gains in protein performance. It applies this technology to develop technical reagents, shelf-stable enzymes for cosmetics, and pulmonary biologic therapeutics for its partners.

3 investors

Aperture Therapeutics uses machine learning to mine genomic and clinical datasets for naturally occurring protective gene variants, then designs oligonucleotide therapeutics that mimic those variants to treat neurodegenerative diseases such as ALS and FTD and delay brain aging. It targets shared drivers of both familial and sporadic disease, often related to neuroinflammation.

3 investors

3 investors

Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutics targeting thromboinflammatory and cardiovascular diseases. The company's lead candidate, APAC, is a heparin proteoglycan mimetic currently in clinical trials.

3 investors

Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.

3 investors

A portfolio biopharmaceutical company translating basic medical research breakthroughs from leading universities into novel therapeutic medicines. The company develops a diversified pipeline of drug candidates through partnerships with top research institutions and selective in-licensing of clinical-stage programs.

3 investors

Aqemia applies atomic-scale physics and generative AI to accelerate drug discovery and molecular design, enabling faster identification of innovative medicines for unmet therapeutic needs. The company uses proprietary deep physics algorithms and machine learning to predict drug properties and design novel molecules, serving pharmaceutical and biotech organizations.

3 investors

Aranda is a pharmaceutical company focused on developing and commercializing prescription and OTC products. The company leverages leadership experience in international pharmaceutical business development and product registration across European markets.

3 investors

Araris develops proprietary antibody-drug conjugate (ADC) linker technology that enables one-step attachment of payloads to native antibodies for targeted cancer therapy. The platform generates stable, homogenous ADCs for oncology applications without requiring antibody re-engineering.

3 investors

Architect Therapeutics is a drug discovery company that uses C-H bond activation chemistry to synthesize novel 3D small-molecule scaffolds and screen them against difficult-to-drug targets. It develops oral therapies with an emphasis on immunology and oncology.

3 investors

Arcutis is a biopharmaceutical company focused on dermatology, developing treatments for immune-mediated skin diseases such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis. It serves patients and healthcare professionals with therapies aimed at improving drug efficacy, safety, and tolerability.

3 investors

Argon AI provides an AI-native workspace designed for life sciences, clinical, and commercial teams that automates research workflows, generates insights from medical data, and accelerates drug development processes.

3 investors

Arialys Therapeutics develops precision medicines designed to block pathogenic autoantibodies that target brain receptors such as the NMDA receptor, aiming to treat neuropsychiatric disorders driven by autoimmune disease. It focuses on autoimmune neuropsychiatry, addressing conditions including encephalitis, schizophrenia, dementia, and cancer-related cognitive impairment.

3 investors

Ariel Precision Medicine offers an AI-driven platform that integrates genomic and clinical data (including EHR/EMR records, lab results, and scientific literature) to produce peer-reviewed, evidence-based reports. It serves clinicians diagnosing complex diseases and therapeutics developers seeking target discovery and patient stratification.

3 investors

Arima Genomics develops DNA-based cancer diagnostics that combine genomic sequence with 3D genome structural information (via Hi-C sequencing) to detect fusions, rearrangements, ecDNA, and other structural drivers of cancer. It serves clinicians and biopharma partners through its Aventa clinical testing brand and translational science collaborations, using routine FFPE tumor samples to guide diagnosis and therapy selection.

3 investors